7 news items
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
VIR
5 Jun 24
:
Title: Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR
29 May 24
, clinical science, clinical operations, drug safety, and pharmacology. Prior to his most recent tenure with Sonoma Biotherapeutics, Dr. Eisner served as CMO
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
(NCT05461170) is evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living
Vir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
VIR
21 May 24
and safety of tobevibart and elebsiran for the participants that were previously reported on at the 2023 American Association for the Study of Liver
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
treatment data on the efficacy and safety of tobevibart and elebsiran for the participants that were previously reported on at the 2023 American
uqqv0dmdazxvmgzc46ayp3j0cahaaf t5g
VIR
13 May 24
comprehensive clinical safety and efficacy data as well as critical insight towards our late-stage development plan and achieving potentially higher rates
9g69z44lge5oeyten7v2vbmpd2shpm5h0kl0fmnosznr6jyf
ANTX
VBIV
VIR
22 Mar 24
developed to treat anxiety and depressive disorders. The study aims to evaluate the safety, tolerability, and PK of BRII-297 in healthy volunteers with data
- Prev
- 1
- Next